Expanding its know-how on AI-based drug discovery, Atomwise has agreed to partner with Bridge Biotherapeutics to discover and develop up to 13 small molecule programmes across multiple therapeutic indications. In the deal worth up to US$1.08 B, the companies will utilise Atomwise’s structure-based AI technology, AtomNet, to identify small molecule candidates for identified targets. Atomwise will investigate Pellino inhibitors with the deal as well as other targets identified by Bridge.